Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

Am J Hematol. 2021 Apr 1;96(4):E95-E98. doi: 10.1002/ajh.26084. Epub 2021 Jan 11.

Jennifer R Brown^{1

2}, Sarah R Walker^{1

2}, Lisa N Heppler¹, Svitlana Tyekucheva³, Erik A Nelson^{1

2}, Josephine Klitgaard¹, Maria Nicolais¹, Yasmin Kroll¹, Michael Xiang¹, Jennifer E Yeh¹, Mousumi Chaudhury¹, Zachary T Giaccone¹, Stacey M Fernandes¹, Eric D Jacobsen^{1

2}, David C Fisher^{1

2}, Arnold S Freedman^{1

2}, Matthew S Davids^{1

2}, Jeffrey G Supko⁴, Catherine Wu^{1

2}, David A Frank^{1

2}

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁴ Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Publication types